by Van Bocxlaer K, McArthur K-N, Harris A, Alavijeh M, Braillard S, Mowbray CE, Croft SL. Pharmaceutics 2021; 13(4):516. doi: 10.3390/pharmaceutics13040516
Summary: Local drug administration could potentially reduce adverse effects and improve treatment adherence compared to current systemic therapies for cutaneous leishmaniasis. The authors report the use of film-forming systems (FFS) for the delivery of DNDI-0690, a compound with potent activity against cutaneous leishmaniasis-causing Leishmania species. Polymeric FFS strongly adhere to the skin, favouring sustained drug delivery, reducing the need for frequent applications, and enhancing patient compliance. Seven polymers were evaluated and two were selected to test delivery of DNDI-0690 in an experimental model of cutaneous leishmaniasis. Although drug delivery into the skin was successful, these FFS systems were not effective for the topical application of DNDI-0690. The convenience, aesthetic, and ability of FFS systems to modulate drug delivery to and into the skin merit further investigation.
